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Abstract 
Objectives: Antibodies against transglutaminase 6 (anti-TG6) have been implicated in 
neurological manifestations in adult patients with genetic-gluten intolerance and it is 
unclear whether autoimmunity to TG6 develops following prolonged gluten exposure. We 
measured the anti-TG6 in children with celiac disease (CD) at the diagnosis time to 
establish a correlation between these autoantibodies and the duration of gluten exposure. 
We investigated a correlation between anti-TG6 and the presence of neurological 
disorders. 
Methods: Anti-TG6 (IgA/IgG) were measured by ELISA in sera of children with biopsy-
proven CD and of children suffering from gastrointestinal disorders. CD-patients positive 
for anti-TG6 were retested after 2 years of gluten-free diet (GFD). 
Results: We analyzed the sera of 274 CD-children and of 121 controls. Anti-TG6 were 
detected in 68/274 (25%) CD-patients and in 19/121 (16%) controls, with significant 
difference between the two groups (p=0.04). None of the CD-patients and of the controls 
testing positive for anti-TG6 were suffering from neurological disorders. Eleven/18 (61%) 
CD-patients with other autoimmune diseases were positive for anti-TG6. In CD-patients a 
significant correlation between the gluten exposure before the CD-diagnosis and anti-TG6 
concentration was found (p=0.006 for IgA; p<0.0001 for IgG). After GFD anti-TG6 
concentrations were significantly reduced (p<0.001). No significant correlation was 
observed between anti-TG6 and anti-TG2 serum concentrations.  
Conclusions: Anti-TG6 are more prevalent in children with untreated-CD in absence of 
overt neurological disorders. The synthesis of the anti-TG6 are related to a longer 
exposure to gluten before the CD diagnosis and the autoimmunity against TG6 is gluten 
dependent and disappeared during GFD.  
 
Keywords: gluten free diet; neurological disorders; transglutaminase 6.  
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What is known/What is new 
 
What is known: 
 Celiac disease (CD) patients may have neurological manifestations triggered by gluten. 
 Transglutaminase 6 (TG6) is expressed in neurons and is targeted by autoantibodies in 
patients with neurological manifestations.  
 In the adult population anti-TG6 antibodies are a sensitive and specific marker of gluten 
ataxia and are gluten dependent. 
 
What is new: 
 The prevalence of anti-TG6 antibodies is 25% in untreated-CD children without 
neurological manifestations and is increased (61%) in untreated-CD children with other 
autoimmune diseases. 
 In the pediatric population anti-TG6 antibodies correlate with the gluten exposure 
duration and disappear during gluten free diet. 
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Introduction  
Celiac disease (CD) is a gluten dependent autoimmune disorder affecting genetically 
predisposed individuals bearing the HLA DQ2 or DQ8. CD related manifestations and 
symptoms are not confined to the gastrointestinal system and they ameliorate following 
strict gluten-free diet (GFD) 1. Extra-intestinal manifestations include neurological, 
obstetric, hepatic, cardiac, dermatological (dermatitis herpetiformis), osteoporosis and 
juvenile chronic arthritis 2–7. Serum antibodies against the autoantigen transglutaminase 
type 2 (anti-TG2) are a hallmark of active CD and represent the first line serological testing 
for CD-diagnosis. In addition to TG2, two more transglutaminase enzymes, type 3 and 6, 
are involved in two distinct gluten-dependent disorders: dermatitis herpetiformis (DH) 8 and 
gluten-ataxia (GA) 9, respectively. Patients suffering from these two clinical conditions 
have serological evidence of these specific autoantibodies and some evidence for a 
causative role has been demonstrated 10,11. Like anti-TG2 antibodies in CD, both the anti-
TG3 and anti-TG6 antibodies are gluten dependent and their blood plasma titers decrease 
significantly in response to a GFD, with concomitant clinical amelioration for patients 
suffering from DH 12 or GA 13. These specific autoantibodies can be useful in the diagnosis 
of such extra-intestinal manifestations. Untreated adult CD patients may also have anti-
TG6 antibodies (range 14-38%) 9,13,14. As yet it is not clear whether these patients are 
susceptible to the development of neurological dysfunction if they continue on a gluten-
containing diet or if indeed they have subtle neurological dysfunction often missed due to 
lack of neurological evaluation. It is also unclear if these patients have anti-TG6 antibodies 
from childhood or whether they go on to produce them later on in life. Anti-TG6 antibodies 
amongst children with untreated CD have never been investigated, and only a single case 
of a child with CD and epilepsy in association with anti-TG6 15 was reported. In this case, a 
dramatic response to the GFD was observed. In this study, we investigated the prevalence 
of the anti-TG6 antibodies in children with newly diagnosed CD. We compared the serum 
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concentration of anti-TG6 with the serum concentration of anti-TG2 at the time of 
diagnosis and following treatment with a GFD, and investigated a potential correlation with 
the duration of exposure to gluten containing diet before the diagnosis.  
Patients and Experimental Procedures  
Subjects and study design. 
The study was performed retrospectively on sera collected from children with biopsy-
proven CD diagnosed using the ESPGHAN criteria 16 at the Institute for Maternal and Child 
Health, IRCCS Burlo Garofolo (Trieste, Italy) between September 2011 and December 
2013. Informed consent for the study was obtained from the parents of 274 children with 
biopsy-proven CD (178 F, 96 M;).  In all of the CD patients intestinal biopsies the typical 
features of gluten sensitive enteropathy (villus atrophy, crypt hyperplasia and intraepithelial 
T lymphocytes density >25 T-cells/100 epithelial cells) were present.  
As a control group we tested the serum samples from 121 children (69F, 52M; median age 
11 years, range 1-16)  suffering from various gastrointestinal disorders (44 with 
gastroenteritis, 17 with esoinophilic esophagitis, 13 with gastro-esophageal reflux, 41 with 
recurrent abdominal pain and 6 with foreign body ingestion) who had also undergone 
gastrointestinal endoscopy and biopsy. 
Serum samples were stored at -30 C and all of the samples were thawed once, before 
being analyzed. All the subjects that tested positive for the anti-TG6 antibodies were 
retested after 24 months of GFD. Moreover, the CD related HLA DQ2/8 haplotypes were 
evaluated among all the CD patients and any control group subjects that tested positive for 
anti-TG6 by PCR. Positive anti-TG6 antibody results were correlated with the presence of 
ataxia or epilepsy by investigating patient records. Written informed consent was obtained 
from the parents of the children enrolled. The study was approved by the independent 
Ethical Committee of the Institute of Child Health IRCCS “Burlo Garofolo” (CE/V-04/2015). 
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Serology and HLA typing.  
Serum IgA/IgG anti-TG2 were measured using an ELISA (Eurospital, Italy) following the 
manufacturer’s instructions with normal values <7 U/I for both A and G immunoglobulin 
isotype. Serum IgA/IgG anti-TG6 were measured by means of an ELISA assay as 
previously described 17. A measurement >75 U/ml for IgA or >34 U/ml for IgG was 
considered positive.  
The susceptibility alleles for CD were determined by PCR with allele specific primers 
identifying DQ2 and DQ8, using Eu-Gene-Risk kit (Eurospital, Italy).  
The assays were performed by operators (LDL, DA, PA, SV, FZ) blinded to the subjects’ 
clinical and hospital laboratory data. 
Statistical analysis. 
Correlation between the anti-TG6 antibody serum concentrations and age at time of CD 
diagnosis were evaluated by using nonparametric Spearman rank test, while the 
correlation between the anti-TG6 antibody and the anti-TG2 antibody serum 
concentrations were evaluated by using linear regression analysis. Statistical comparison 
between the serological data of the different groups was performed using the Fischer’s 
exact test, and the sequential serum samples were also compared using Wilcoxon signed 
rank test. A value of p<0.05 was considered significant. 
Results 
Serum autoantibody analysis. 
Children with biopsy proven CD (274: 178F, 96M; median age 7 years, range 1-17) and 
children (121: 69F, 52M; median age 11 years, range 1-16) suffering from other 
gastrointestinal disorders (control group: 44 with gastritis, 17 with eosinophilic esophagitis, 
13 with gastro-esophageal reflux, 41 with recurrent abdominal pain and 6 with foreign body 
ingestion) were investigated for TG2 and TG6 autoantibodies: 
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All of the CD patients tested positive for HLA DQ2 or DQ8 and anti-TG2 autoantibodies. 
Serum IgA anti-TG2 in this group ranged from 8 to 280 U/I (mean concentration 60±52 U/I, 
normal values <7 U/I) and serum IgG anti-TG2 from 0 to 500 U/I (39±62 U/I, normal values 
<9 U/I). In six patients with total IgA deficiency, IgG anti-TG2 titers above the threshold 
value were detected (mean concentration 82±25 U/I). Anti-TG6 antibodies were found in 
68/274 (25%) CD-patients (36 tested positive for IgG, 25 for IgA and 7 for both IgA and 
IgG) (Fig.1). There was a significant difference compared to controls (p=0.04). There was 
no mention of any neurological disorder in either patients positive or negative for anti-TG6 
antibodies. This was based on retrospective evaluation of the patients’ records. Eighteen 
out of 274 CD-patients were suffering from other autoimmune diseases (thyroiditis, type 1 
diabetes, dermatitis herpetiformis) and 11 of them (61%) tested positive for anti-TG6 (9 for 
IgG and 2 for IgA).  
No statistically significant correlation was observed between anti-TG6 and anti-TG2 serum 
antibody concentrations (Fig.2), in line with data from other patient cohorts 9,11. There was 
a significant correlation between the duration of the gluten exposure before the CD-
diagnosis and serum concentration of both IgA (p=0.006) and IgG (p<0.0001) anti-TG6 
antibodies (Fig.3).  
None of the controls tested positive for the anti-TG2 antibodies (mean concentration 1.5±2 
for IgA, 3.5±2 for IgG U/I) and their intestinal biopsies did not demonstrate the CD-related 
abnormalities. Two out of 121 subjects belonging to subjects with gastrointestinal 
disorders (control group) were affected by IgA deficiency, and anti-TG6 IgA were thus 
measured in 119 patients. Anti-TG6 antibodies were found in 19/121 (16%) subjects in the 
control group (12 tested positive for IgG, 5 for IgA and 2 for both IgA and IgG) (Fig.1). 
Among the 19 subjects positive for anti-TG6 antibodies, 8 were suffering from recurrent 
abdominal pain (42%), 4 from gastritis (21%), 4 from gastro-esophageal reflux (21%) and 
3 from eosinophilic esophagitis (16%). The CD-related HLA was present in 6 of 19 (31%,   
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all six tested positive for  HLA DQ2). None of the controls were suffering from neurological 
disorders. 
CD-patient follow-up after GFD. 
Forty out of 68 (59%) children with CD that tested positive for anti-TG6 antibodies (18 
tested positive for IgG, 17 for IgA and 5 for both IgA and IgG) were re-tested after 24 
months of GFD. Thirty-eight out of 40 (95%) tested negative for anti-TG2 antibodies and 
36/40 (90%) tested negative for anti-TG6 antibodies, with significant decrease in both IgA 
and IgG antibody serum concentration before and after GFD (p<0.001) (Fig.4). Two out of 
the four subjects still positive for anti-TG6 did not follow gluten-free diet and were positive 
for anti-TG2 antibodies as well (IgA 40 and 65 U/I, IgG 39 and 25 U/I). 
Discussion  
In  adult patients with CD presenting with neurological manifestations there is a significant 
difference of age at presentation when compared to adult patients with CD presenting to a 
gastroenterologist with the classic symptoms (53 vs 42 years)14. This therefore raises the 
question as to whether the respective underlying autoimmune responses develop at 
different consecutive phases in life, particularly in light of the fact that neurological 
problems are rarely seen in children with CD. Given that neurological manifestations are 
associated with an autoimmune response to TG6,2,9,13 we investigated whether children 
presenting with CD had circulating autoantibodies to TG6. Here, we show for the first time 
that such autoantibodies can be detected in young children at time of presentation with 
considerable frequency, suggesting that autoantibodies to different transglutaminase (TG)  
isozymes are developed simultaneously and not during different phases of life, i.e. as a 
late stage disease sequelae. 
Interestingly, our data show a significantly higher prevalence/concentration of anti-TG6 
antibodies among children with a longer exposure to gluten containing diet before the CD-
11 
 
diagnosis. Moreover, these autoantibodies are gluten dependent, with elimination of anti-
TG6 antibodies in 90% of patients following the GFD. This is in line with what is seen in 
pediatric CD patients who are positive for other organ-specific autoantibodies (e.g. anti-
thyroid peroxidase antibodies, glutamic acid decarboxylase antibodies, anti-insulin 
antibodies) 18. Such autoantibodies may disappear following a GFD 18,19, raising the 
possibility that in some instances gluten-dependent T cells can drive multiple immune 
responses and hence, that GFD could potentially prevent the development of neurological 
deficits or secondary autoimmune diseases such as type 1 diabetes and autoimmune 
thyroiditis in patients with genetic gluten intolerance.  
We have found the prevalence of anti-TG6 antibodies to be 25%. This compares to a 
prevalence of 38% in adult patients of European Caucasian descent with newly diagnosed 
CD but from a different geographical region (UK) 14. The geographical selection (ethnicity) 
may well be an important factor as differences in the prevalence of anti-TG6 antibodies 
amongst adult patients with CD have been identified (38% in adult CD patients from the 
UK vs 14% in adult CD patients from Finland) 13,14. This may be one possible explanation 
to variations in the prevalence of neurological manifestations amongst patients with gluten 
related disorders in different countries. The overall prevalence of anti-TG6 antibodies in 
our control group was 16% (specificity 84%) which is higher than what has been found in 
healthy controls (4%) 13,17. This is likely to relate to the fact that most of these controls 
suffered from other gastrointestinal disorders associated with chronic inflammation with 
only six (with foreign body ingestion) being free from gastrointestinal disease, none of 
which were positive for anti-TG6 antibodies. It remains to be seen if some of these patients 
which carry the genetic gluten intolerance (HLA DQ2/8) may develop CD in the future.  
Of interest is also our finding that 11/18 (61%) CD patients suffering from autoimmune 
diseases (thyroiditis, diabetes, dermatitis herpetiformis) tested positive for anti-TG6 
antibodies, a significantly higher prevalence compared to the CD population as a whole. 
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This raises the possibility that the presence of anti-TG6 antibodies may be a marker of 
‘multiple’ autoimmunity, perhaps signifying a different stage of the immune response.  
Our finding of autoantibodies to different transglutaminase  isozymes in children at 
presentation is consistent with the current view that B cells/plasma cells targeting TG6 
originate independently from those targeting TG2 and not due to epitope spreading. This is 
supported by the fact that TG6 can generate gluten peptide-derivatives that drive both T 
and B cell responses 20, anti-TG6 antibodies can be the only autoantibodies present in 
patients with genetic gluten intolerance 9, and analysis of clonal antibodies from celiac 
patients established that anti-TG antibodies are isozyme specific 21. Hence, not 
surprisingly, the serum concentration of anti-TG6 antibodies among untreated CD patients 
examined here showed no correlation to the presence of high anti-TG2 antibody serum 
concentration. This is consistent with the observation that anti-TG6 antibodies are present 
in up to 67% of adult CD patients who present with neurological dysfunction as opposed to 
38% in adults with CD who present to gastroenterologists, yet the prevalence of TG2 
antibodies in the 2 groups is similar (91-97%) 14. A similar observation can also be seen in 
patients with dermatitis herpetiformis where the immunological response targets TG3. 
Circulating anti-TG3 antibodies were found in 86% of patients with DH as opposed to 24% 
in patients with CD, while TG2 antibodies showed a similar prevalence in both DH (86%) 
and CD (92%) patients 12. The role of circulating TG isozyme-specific autoantibodies in 
development of extraintestinal disease has indeed been demonstrated in animal models 
10,11
.   
The absence of neurological dysfunction amongst children with CD positive for anti-TG6 
may be due to a number of factors. Firstly, our assessment of any neurological problems 
was retrospective and based just on the clinical records. None of the patients were 
evaluated by a neurologist or underwent full neurological examination and brain imaging to 
look for any evidence of neurological dysfunction. Secondly, neurological manifestations in 
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children with CD are said to be rare when compared to the adult population. An immune 
response targeting TG2 drives overt tissue destruction in the gut (due to antigen 
abundance) in short succession but this is not the case for an immune response targeting 
TG6. Hence, extraintestinal manifestation may be slow progressing or latent. It is also 
likely that neurological problems that are subclincal are missed for prolonged periods, 
hence the typically late diagnosis. In the case of TG6 autoantibodies, it is of course also 
possible that circulating autoantibodies by themselves are not sufficient to precipitate 
neurotoxicity as the CNS is shielded by the blood brain barrier but that an additional event 
is necessary for which there is an increased risk with age. The implication of this finding is 
that patients with the classic presentation of gastrointestinal symptoms are more likely to 
be diagnosed with CD than those with extra-intestinal manifestations. Extra-intestinal 
manifestations are a late phenomenon, perhaps associated with only mild gastrointestinal 
disease as a consequence of a different bias of the immune response. Evidence in support 
of this comes from the fact that the prevalence of DH in Finland has dramatically 
decreased since the introduction of CD screening programs 22. 
It remains to be seen if patients with anti-TG6 antibodies and no enteropathy who do not 
go on a GFD may be at risk of developing neurological dysfunction after prolonged 
exposure to gluten. Careful follow up of those patients in the control group that are positive 
for anti-TG6 may be advised and of interest. 
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Figure legend 
Fig.1 Serum concentration of IgA and IgG anti-TG6 antibodies in the study groups. The 
cut-off limits for both IgA (>74 U/ml) and IgG (>34 U/ml) are indicated by the thin lines. CD: 
children with celiac disease. 
 
Fig.2 Linear regression analysis regarding the relationship between the serum 
concentrations of anti-TG6 antibodies and of anti-TG2 antibodies in CD-patients. No 
statistically significant relationship between the serum antibody concentrations against the 
two antigens was found.  
 
Fig.3 Correlation analysis of age (corresponding to time of gluten exposure) at CD-
diagnosis with the IgA and the IgG anti-TG6 serum concentrations. A statistically 
significant relationship was found with both IgA and IgG anti-TG6. 
 
Fig.4 CD patients tested positive for IgA/IgG anti-TG6 at the diagnosis time during the 
gluten containing diet (GCD) and after 24 months of gluten-free diet (GFD). 
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